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THE COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL
CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL
POLYSACCHARIDE VACCINE (PPV23) IN TAIWAN
Wu DBC1, Chang CJ2, Chien L2, Fang HCH3, Roberts CS4
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High rates of pneumococcal diseases occur despite the availability of 23-valent
pneumococcal polysaccharide vaccine (PPV23) in the elderly aged above 65 in Tai-
wan. A 13-valent pneumococcal conjugate vaccine (PCV13) is developed for use in
high-risk adults. OBJECTIVES: To examine the health and economic impact of
PCV13 compared with PPV23 in Taiwan.METHODS: An age-stratified (18-49, 50-64,
65-74, 75-84, 85-99) micro-simulation Markovmodel was developed and populated
with local data inputs to simulate the potential public health and economic out-
comes of PCV13 versus PCV23 against invasive pneumococcal diseases (meningitis
and bacteremia) and all-cause pneumonia when used as routine vaccination of
infants in Taiwanover a life-timehorizon. Costs include directmedical cost such as
hospitalization, medical outpatient visits, medications and indirect cost. Both ep-
idemiological and cost data inputs were derived retrospectively from National
Health Insurance Reimbursement Database and public sources where available.
The study was performed from both payer and societal perspectives using 3%
discount rate for both costs and life years. Sensitivity analyses were conducted to
test the robustness of model outcomes. RESULTS: Model projected that PCV13
vaccination compared with PPV23 can prevent 96, 4,549, 1,110,253 and 1,548,947
cases of meningitis, bacteremia, outpatient pneumonia, and inpatient pneumonia
respectively while saving 167,065 deaths, equivalent to 201,166 life years. PCV13
vaccination is estimated to save an direct (indirect) cost of NTD113,952M
(NTD17,182M) over 82 years. Given market price assumption of one dose of PCV13
and PPV23 (NTD3,000 vs. NTD700), PCV13 vaccination on adults is expected to lead
to NTD57,334 (NTD36,476) per life year saved in 50-64 age group and is cost-saving
for all elder age groups from both payer (societal) perspective compared to PPV23.
CONCLUSIONS: PCV13 adult vaccination in Taiwan was estimated to reduce the
burden of pneumococcal diseases and expected to be cost-effective from both
payer and societal perspectives.
CE2
COST-EFFECTIVENESS OF THE REAL-WORLD USE OF NUCLEIC ACID TEST
SCREENING TO DONATED BLOOD FOR HEPATITIS B, HEPATITIS C, AND HUMAN
IMMUNODEFICIENCY VIRUS: EXPERIENCE FROM TAIWAN, A COUNTRY WITH A
HIGH PREVALENCE OF HEPATITIS B AND C INFECTIONS
Wu GHM1, Wang YC1, Lin SJ2, Lin KS2
1Center for Drug Evaluation, Taipei, Taiwan, 2Taiwan Blood Services Foundation, Taipei, Taiwan
OBJECTIVES: To examine the cost-effectiveness of adding nucleic acid testing
(NAT) to enzyme immunoassay (EIA) screening for hepatitis B (HBV), hepatitis C
(HCV), and human immunodeficiency virus (HIV) in Taiwan based on the govern-
mental perspective. METHODS: A Markov model depicting the natural history of
HBV, HCV, and HIV infections and subsequent illnesses for blood recipients in
Taiwan was developed to evaluate the cost-effectiveness of adding five different
NAT screening strategies employing different test systems and pool sizes to EIA
screening, including cobas TaqScreen multiplex in pools of 6 (EIACobas6), Proce-
lix Ultrio in individual donations (EIAUltrio1), or pools of 4 (EIAUltrio4), and
Procelix Ultrio Plus in individual donations (EIAUPlus1), or pools of 8
(EIAUPlus8). The population size and characteristics of the recipients were de-
rived from the National Health Insurance (NHI) data. Transition probabilities and
utilities were abstracted from published literature. Efficacy and screening costs
were obtained from a nationwide NAT screening program launched in Taiwan.
Medical costs incurred by infections and subsequent illnesses were obtained from
the NHI and published literature based on Taiwanese data. Both costs and health
outcomes were discounted at 3%. All costs were presented in 2012 USD. Probabi-
listic sensitivity analyses were performed. RESULTS: A 270,535-recipient cohort
based on the annual number of recipients in Taiwan, was simulated. The model
predicted that for variousNAT screening strategies 120-400 infectionswere averted
with additional 6.8-13.6 million NAT screening costs, corresponding to 34,200-
72,400 USD per infection averted, and the lifetime incremental costs per quality-
adjusted life-year (QALY) gained were 48,600-72,400 USD/QALY. Wide variation,
however, was seen and the probability that NAT being cost-effective was 18-30%.
CONCLUSIONS: EIACobas6 and EIAUPlus8 are the two strategies of better cost-
effectiveness. At the threshold of three-fold GDP per capita (55,800 USD/QALY),
EIACobas6 and EIAUPlus8 may be considered as cost-effective in Taiwan but
with high uncertainty.
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HYPERBARIC OXYGEN THERAPY FOR THE TREATMENT NON-NEUROLOGICAL
SOFT TISSUE RADIATION INJURIES- A COST EFFECTIVENESS ANALYSIS
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OBJECTIVES: To investigate the cost effectiveness of Hyperbaric oxygen therapy (HBOT)
for the treatment of non-neurological soft tissue radiation injuries.METHODS: The eco-
nomic evaluation adopted a decision analytic framework comparingHBOT to usual
care for the treatment of non-neurological soft tissue radiation injuries. The incre-
mental costs per patient wound healed/improved were presented. Estimates of
effectivenesswere obtained from a published RCT (Clarke et al, 2008). Resource use
was determined from HIC data (Medicare and Pharmaceutical Benefits Schemes),
the Australian Department of Health and Ageing and expert opinion. RESULTS: For
the base case analysis, significant/moderate improvement or complete wound
healing was demonstrated in 88.9 per cent of patients who received HBOT for soft
tissue radiation injuries, and the comparable figure for usual care was 62.5 per cent
of patients. Therefore providing HBOTwould result in an additional 26.4 per cent of
patients being successfully treated. The average cost accrued in the HBOT-treated
group was $11,753 per patient compared to $12,482 in the usual care group. This
represents a cost savings of $728 per patient, meaning that HBOT dominates usual
care (i.e. HBOT is less expensive and is more effective). CONCLUSIONS: The results
indicate that HBOT is a cost-effective alternative to usual care for the treatment of
soft tissue radiation injuries. There is considerable uncertainty around the esti-
mates of usual care due to the complexity of the treatment pathway.
CE4
COST-EFFECTIVENESS OF DABIGATRAN COMPARED TO GENOTYPE-GUIDED
WARFARIN DOSING FOR STROKE PROPHYLAXIS IN ATRIAL FIBRILLATION
PATIENTS
Lim KJ1, Tan DSY2, Wee HL1
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OBJECTIVES: To evaluate the cost-effectiveness of high-dose dabigatran (150 mg
twice daily) against genotype-guided warfarin dosing in nonvalvular atrial fibrilla-
tion (AF) patients requiring anticoagulation for stroke prevention from the US pay-
er’s perspective. Conventional dose-adjusted warfarin has been the main antico-
agulation strategy for decades. Newer treatment strategies such as oral direct
thrombin inhibitor dabigatran and genotype-guided warfarin dosing offer several
advantages over warfarin. To the best of our knowledge, there is no head-to-head
study evaluating the cost-effectiveness of dabigatran and genotype-guided warfa-
rin dosing versus conventional warfarin.METHODS:AMarkov decisionmodel was
constructed to derive the incremental cost effectiveness ratios (ICERs; in US$ per
QALY) of dabigatran and genotype-guided warfarin dosing versus conventional
warfarin in a hypothetical cohort of 70-year-old patients with newly-diagnosed AF
and moderate stroke risk (CHADS2 score1). The time horizon is 20 years. Costs,
utilities and adverse event rates were derived from published studies. One-way
and two-way sensitivity analyses were performed. RESULTS: At an ICER of
US$17,260 per QALY, high-dose dabigatran provided an additional 0.30 QALYs over
genotype-guidedwarfarin dosing in the base-case. Themodelwas only sensitive to
drug costs. Among patients with amoderate to high intracranial hemorrhage (ICH)
risk, at the current retail price of US$8 a day, high-dose dabigatran was the most
cost-effective option for all stroke risk groups. Conventional warfarin dosing re-
mains most cost-effective for patients with a low ICH risk. CONCLUSIONS: In 70-
year-old patients with nonvalvular AF andmoderate stroke risk (CHADS2 score1),
high-dose dabigatran was cost-effective compared to genotype-guided warfarin
dosing, at National Institute for Health and Clinical Excellence’swillingness-to-pay
thresholds of US$30,000 to US$45,000 (£20,000 to £30,000) per QALY gained. By
using a common Markov model to compare three treatments, we overcome the
limitations of the conventional league table approach (limited comparability due to
differences in models used across studies).
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OBJECTIVES: Statins have potential protective effects against cancers but no stud-
ies have focused on patients with chronic hepatitis B virus (HBV) infection. The
purpose of this study was to investigate the association between the use of statins
in HBV-infected patients and the risk of hepatocellular carcinoma (HCC).
METHODS: We conducted a population-based cohort study from the Taiwan Na-
tional Health Insurance Research Database. A total of 33,413 HBV-infected patients
were included as the study cohort. Each subject was individually tracked from 1997
to 2008 to identify incident cases of HCC since 1999. Subsequent use of statin, other
lower-lipid agents, aspirin, and angiotensin-converting enzyme inhibitors were
identified. Cox proportional hazard regressions were employed to calculate the
hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between
the use of statins and the occurrence of HCC in the HBV-infected cohort. RESULTS:
There were 1,021 HCC cases from the HBV cohort during follow-up periods of
328,946 person-years; the overall incidence rates were 310.4 cases per 100,000 per-
son-years, respectively. There was a dose–response relationship between statin
use and the risk of HCC in the HBV cohort. The adjusted HRs were 0.66 (95% CI,
0.44–0.99), 0.41 (95% CI, 0.27–0.61), and 0.34 (95% CI, 0.18–0.67) for statin use 28-90,
91-365, and  365 cumulative defined daily doses (cDDD), respectively, relative to
no statin use ( 28 cDDD). CONCLUSIONS: Statin use may reduce the risk for HCC
in HBV-infected patients in a dose-dependent manner. Further mechanistic re-
search is needed.
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HOW EARLY-STAGE NON-PERSISTENCE AND NON-ADHERENCE TO ADJUVANT
HORMONAL THERAPY ASSOCIATED WITH POSTMENOPAUSAL BREAST CANCER
MORTALITY IN TAIWAN
Hsieh KP1, Chen LC2, Chang CS1, Yang YH1
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OBJECTIVES:Medical adherence to hormone therapy (HT: including tamoxifen and
aromatase inhibitors [AIs]) has been reported as an important prognosis factor for
breast cancer women. Since AIs is not the first-line treatment in postmenopausal
patients by the reimbursement policy in Taiwan, it is of interested to investigate
how the early-stage non-persistence and non-adherence to HT associated with
mortality of postmenopausal breast cancer patients. METHODS: The Taiwan
Health Insurance Research Database (NHIRD) was used to identify 17,101 newly
diagnosed (1999-2007) breast cancer women who were aged over 50 years olds and
received surgery (OP) and HT. The cancer treatments were further categorized into
adjuvant chemotherapy and radiation therapy (CT/RT), CT/nonRT, nonCT/RT and
nonCT/nonRT. The HT prescriptions were categorized into tamoxifen only and
tamoxifen/AIs. The prescription gap (PG) and medication possession ratio (MPR)
were calculated. Any PG180 days in the first treatment year and MPR80% were
defined as ‘early-stage non-persistence’ and ‘non-adherence’. Cox regressions
were used to estimate hazard ratios (HRs). RESULTS: There were 4.97% and 16.83%
identified as ‘early-stage non-persistence’ and ‘non-adherence’ toHT, respectively.
The MPRs of HT were similar across the four cancer treatment groups, but those
received CT/nonRT (5.69%) and CT/RT (6.92%) had a significant higher non-persis-
tence rate. Non-persistence in the first year (CT/RT: HR1.11, 95% CI0.86-1.45;
CT/nonRT: HR1.47, 95% CI1.17-1.85; nonCT/RT: HR2.34, 95% CI1.33-4.12;
nonCT/nonRT: HR2.19, 95% CI1.59-3.00) and non-adherence (CT/RT HR1.29,
95% CI1.09-1.53; CT/nonRT: HR1.40, 95% CI1.21-1.62; nonCT/RT: HR1.08, 95%
CI0.74-1.57; nonCT/nonRT: HR1.10, 95% CI0.92-1.31) were associated with in-
creased mortality. The non-persistence and non-adherence were significantly as-
sociated with increased risk of mortality in tamoxifen/AIs. CONCLUSIONS: Our
results support the association of early-stage non-persistence and non-adherence
toHTwith increasingmortality in postmenopausal breast cancer patients. It is vital
to improve prescribing persistence and adherence for enhancing clinical outcomes
and maximizing the efficiency of medical utilizations.
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COST-EFFECTIVESSNESS ANALYSIS OF TREATMENTS IN ADULT CANCER
PATIENTS WITH LOW RISK FEBRILE NEUTROPENIA IN THAILAND
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OBJECTIVES: The general febrile neutropenia (FN) treatment in cancer patients in
Thailand is hospitalized intravenous antibiotics. Clinical evidence indicated the
efficacy of oral antibiotic treatment and early hospital discharge in the treatment of
FN patients. This study aimed to assess the cost effective treatment strategy for
adult cancer patients with low risk FN in Thailand. METHODS: A decision tree
model was constructed to compare 3 strategies: 1) treatment with ceftazidime in
hospital (HosIV); 2) treatment with oral amoxicillin-clavulanate plus ciprofloxacin
in hospital (HosPO); and 3) treatment with oral amoxicillin-clavulanate plus cipro-
floxacin and then early discharge in 24-48 hr after observing in hospital (Early D/C).
Health care perspective was used; hence, only direct medical costs (drug, hospital-
ization, out patient visit, and laboratory costs) were included. Cost data were ob-
tained fromLopburi Cancer Center. Outcomewasmeasured as quality-adjusted FN
episodes (QAFNE)which considered only 1 FN episode. Effective datawere based on
literature review. Incremental cost-effectiveness ratio (ICER)was analyzed. A series
of one-way sensitivity analyses were performed. RESULTS: In the base casemodel,
HosPO and Early D/Cwere cost saving when compared with HosIV. The cost saving
was equal to 64,028 and 65,801 THB respectively. Early D/C was themost dominant
strategy with lowest cost and highest QAFNE (5,686 THB and 0.63 QAFNE). The
result of one-way sensitivity analysis indicated that drug costs, utility for inpatient
IV, utility for inpatient oral and utility for early discharge showed the impact on
ICER.CONCLUSIONS: BothHosPO and Early D/C strategiesweremore cost effective
than HosIV in adult cancer patient with low risk FN in Thailand.
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INPATIENT TREATMENT PATTERNS AND HEALTH CARE EXPENDITURES FOR
HEPATOCELLULAR CARCINOMA AMONG POPULATION WITH URBAN BASIC
HEALTH INSURANCE IN CHINA
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OBJECTIVES: To summarize current hepatocellular carcinoma (HCC) treatment
patterns andhealth care expenditures during hospitalization amongChina’s urban
basic health insurance (BHI) beneficiaries and to identify trend in HCC treatment
expenditures from 2008 to 2010. METHODS: This was an encounter-based retro-
spective study using hospitalization claims database of the urban BHI enrollees.
Study subjects were patients aged 18 years or older, with the China urban citizens’
or employees’ BHI plan, and had at least one hospital admission with a discharge
diagnosis code of HCC (ICD-10 codes: C22.0 and C22.9) between 2008 and 2010.
Descriptive statistical analyses of treatment patterns and expenditures were
conducted. RESULTS: Totally, 2,765 hospitalization claims met inclusion criteria
and were extracted from the database. Systemic therapy (predominantly tradi-
tional Chinese medicine) was involved in 72% of hospitalizations and transarterial
chemoembolizationwas involved in 27%, followed by palliative therapy only (21%),
local ablation (5%), liver resection (4%), and radiation (3%). Thirty-five percent of
hospitalizations involved combined treatments. On average, HCC treatment ex-
penditure was CNY11,243 per hospitalization in 2008–2010, with annualized in-
crease of 21% from 2008 to 2010. The BHI plan covered a three-year average of 68%
(CNY7,613) of total expenses, while copayment accounted for 20% (CNY2,234).
Other self-paid expenses stabilized at CNY1,400 in 2008–2010. Length of stay
dropped from 21.0 days in 2008 to 17.2 days in 2010, yet the daily expense rose from
CNY460 to CNY848. CONCLUSIONS: Various treatments were used by hospitalized
HCC patients with urban BHI coverage. The most often used treatment was sys-
temic therapy. Health care expenditures per hospitalization increased tremen-
dously from 2008 to 2010. However, the drugs patients purchased outside hospitals
could not be captured in this database, which might underestimate the expendi-
tures. Other limitations include lack of information at patient level and on disease
stages and grades.
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OBJECTIVES: To summarize the progress of epidemiology, treatment, and eco-
nomic burdens of type 2 diabetesmellitus (T2DM)with nephropathy complications
in China. METHODS: A systematic review method was performed to search and
refine the evidence of existing English and Chinese researches on T2DM and dia-
betic nephropathy. Literatures were searched from various databases including
Pubmed, Web of science, CNKI, etc. Five inclusion criteria include disease (T2DM
and nephropathy), population (Chinese patients), prevalence, treatment proce-
dure, and disease burden. Quality assessment and data extraction were imple-
mented by two reviewers independently and the differences between them were
resolved by consensus. RESULTS: Fifty-one articles were included in the review.
The results showed that the rising prevalence rate of diabetes in China has reached
a high level. The mortality of diabetic nephropathy (DN) has higher proportion of
34% in totalmortality of T2DMpatients than other DM complications, although the
researches related to DN are not yet enough. The western medicine treatment
strategies of T2DMwith chronic kidney diseasesweremore instructional, while the
treatment with Chinese herbal medicine was based on the principle of ‘syndrome
differentiation’, resulting in the difficulty to carry out multicenter clinical re-
searches to evaluate the treatment effect. Diabetes and its complications have
brought a heavy burden in China. The total economic burden of DM and its com-
plications reached 247.8 billion RMB in 2007 and varied among different cities and
between urban and rural areas. CONCLUSIONS: Evidence of prevalence and disease
burden of diabeteswasnot comprehensive in current researches onChinese patients,
especially for diabetic nephropathy. Information of diabetic complications should be
included in the content of cross-sectional diabetes surveys to provide more informa-
tion of the incidence and prevalence of DN. More intervention researches should be
conducted to actively prevent DM and chronic complications such as DN.
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VITAMIN D DEFICIENCY AND DIABETES: PERCEPTIONS OF PHARMACISTS AND
PHYSICIANS
Jalundhwala F1, Majumdar A1, Malthankar S1, Jalundhwala Y2
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OBJECTIVES:With an estimated 62.22million people suffering fromdiabetes, India
is fast becoming the “Diabetes Capital of theWorld”. VitaminD deficiency has been
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